Wuhan YZY Biopharma Co., Ltd. Class H (HK:2496) has released an update.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Wuhan YZY Biopharma Co., Ltd., a publicly listed company in China, has announced the composition of its board of directors and their roles within the company. The board includes a mix of executive, non-executive, and independent non-executive directors, with Dr. Zhou Pengfei serving as Chairman and CEO. The company’s governance structure is further supported by three committees focusing on audit, nomination, and remuneration.
For further insights into HK:2496 stock, check out TipRanks’ Stock Analysis page.